TNFSF10 and cardiomyopathy: Study has shown that it can promote the survival and proliferation of primary human vascular endothelial cells by activating the AKT pathway [13], and studies have also showed that administration in the form of recombinant soluble TRAIL or AAV-TRAIL expression viral vectors reduces the development of cardiomyopathy in a ApoE-/-diabetic mouse model and shows potential cardioprotective activity [24].